Literature DB >> 21937741

A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat.

Eugene H Herman1, Alan Knapton, Elliot Rosen, Karol Thompson, Barry Rosenzweig, Joel Estis, Sara Agee, Quynh-Anh Lu, John A Todd, Steven Lipshultz, Brian Hasinoff, Jun Zhang.   

Abstract

Cardiotoxicity was an unanticipated side effect elicited by the clinical use of imatinib (Imb). This toxicity has been examined in only a limited number of experimental studies. The present study sought, by a variety of approaches, to identify important characteristics of Imb-induced cardiac alterations. Male spontaneously hypertensive rats (SHRs) received oral doses of 10, 30, or 50 mg/kg Imb or water daily for 10 d. Cardiac lesions, detected at all doses, were characterized by cytoplasmic vacuolization and myofibrillar loss. In a second experiment, cardiac lesions were found in Sprague Dawley (SD) and SHR rats given 50 or 100 mg/kg Imb for 14 d. Mean cardiac lesion scores and serum levels of cardiac troponin I were higher in SHRs than in SD rats. Imb induced myocyte death by necrosis, autophagy, and apoptosis. Dose-related increases in cardiac expression were observed for several genes associated with endoplasmic reticulum stress response, protein folding, and vascular development and remodeling. Imb caused alterations in isolated myocytes (myofibrillar loss, highly disrupted and disorganized sarcomeric α-actinin, apoptosis, and increased lactate dehydrogenase release) at low concentrations (5 mM). The authors conclude that Imb exerts cardiotoxic effects that are manifest through a complex pattern of cellular alterations, the severity of which can be influenced by arterial blood pressure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21937741     DOI: 10.1177/0192623311419524

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  16 in total

Review 1.  Cardiovascular disease in adult survivors of childhood cancer.

Authors:  Steven E Lipshultz; Vivian I Franco; Tracie L Miller; Steven D Colan; Stephen E Sallan
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

Review 2.  Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?

Authors:  Tarek Magdy; Brian T Burmeister; Paul W Burridge
Journal:  Pharmacol Ther       Date:  2016-09-05       Impact factor: 12.310

Review 3.  Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors:  Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal:  Clin Biochem       Date:  2014-11-07       Impact factor: 3.281

4.  Imatinib activates pathological hypertrophy by altering myocyte calcium regulation.

Authors:  Larry A Barr; Catherine A Makarewich; Remus M Berretta; Hui Gao; Constantine D Troupes; Felix Woitek; Fabio Recchia; Hajime Kubo; Thomas Force; Steven R Houser
Journal:  Clin Transl Sci       Date:  2014-06-16       Impact factor: 4.689

Review 5.  Cardiomyocyte autophagy and cancer chemotherapy.

Authors:  Dan L Li; Joseph A Hill
Journal:  J Mol Cell Cardiol       Date:  2013-11-14       Impact factor: 5.000

6.  Cardiovascular differentiation of imatinib and bosutinib in the rat.

Authors:  Jonathan R Heyen; Wenyue Hu; Joseph Jamieson; Stephane Thibault; Minerva Batugo; Cho-Ming Loi; Leigh Ann Burns-Naas; Aileen D McHarg; Bart Jessen
Journal:  Int J Hematol       Date:  2013-10-19       Impact factor: 2.490

7.  Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Authors:  Brian B Hasinoff; Xing Wu; Daywin Patel; Ragu Kanagasabai; Soumendrakrishna Karmahapatra; Jack C Yalowich
Journal:  J Pharmacol Exp Ther       Date:  2015-12-11       Impact factor: 4.030

8.  The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling.

Authors:  Gregory J Kaczorowski; Maria L Garcia; Jacob Bode; Stephen D Hess; Umesh A Patel
Journal:  Front Pharmacol       Date:  2011-12-13       Impact factor: 5.810

9.  Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity.

Authors:  Gregory Marslin; Ann Mary Revina; Vinoth Kumar Megraj Khandelwal; Krishnamoorthy Balakumar; Jose Prakash; Gregory Franklin; Caroline J Sheeba
Journal:  Int J Nanomedicine       Date:  2015-04-24

Review 10.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.